First patients test novel Triple-Target weapon against tough lymphomas
NCT ID NCT07308132
Summary
This is the first human study of a new experimental drug called JNJ-95566692, a triple-target antibody designed to fight B-cell non-Hodgkin lymphoma. The main goal is to find safe and tolerable doses, both alone and when combined with another drug, for people whose cancer has returned or stopped responding to standard treatments. Researchers will also look for early signs that the treatment can shrink tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA, NON-HODGKIN are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ankara Universitesi Hastaneleri Tibbi Farmakoloji Anabilim Dali Faz 1 Klinik Arastirma Merkezi
RECRUITINGAnkara, 06620, Turkey (Türkiye)
-
Koc Universitesi Hastanesi Faz 1 Klinik Arastirma Merkezi
RECRUITINGIstanbul, 34010, Turkey (Türkiye)
-
Macquarie University Hospital
RECRUITINGNorth Ryde, 2109, Australia
-
Peter MacCallum Cancer Centre
RECRUITINGMelbourne, 3000, Australia
-
SBU Ankara Dr. Abdurrahman Yurtaslan Onkoloji Egitim ve Arastirma Hastanesi Faz 1 Merkezi
RECRUITINGAnkara, 06200, Turkey (Türkiye)
-
Scientia Clinical Research
RECRUITINGRandwick, 2031, Australia
-
UZ Antwerpen
RECRUITINGEdegem, 2650, Belgium
Conditions
Explore the condition pages connected to this study.